Alys Pharmaceuticals’ Post

Hematologic Malignancies Key Abstracts to watch during ASCO 2024. Leading companies such as Janssen Inc., Novartis, Genmab, Pfizer, Innate Pharma, and Sanofi are preparing to unveil their latest data and final analyses at the upcoming conference. The spotlight will be on key abstracts expected to make a lasting impact, generating significant interest and discussion throughout the event. In the last decade, the treatment options for hematologic malignancies have undergone significant expansion, notably with the advent of novel CAR T-cell therapies. These groundbreaking treatments have greatly enhanced patient outcomes. However, clinicians frequently encounter difficulties in identifying suitable candidates for these therapies, particularly among elderly individuals. Stay tuned with DelveInsight Business Research LLP for all the latest advancement in the Hematologic Malignancies set to be presented during the meeting @ https://lnkd.in/gd3txwQP #HematologicMalignancies #CARTTherapies #JanssenInnovates #NovartisResearch #GenmabAdvances #PfizerResearch #InnatePharmaUpdates #SanofiInnovation #ConferenceSpotlight #AbstractAnalysis #HematologyConference #ElderlyPatients #PersonalizedTherapy #ClinicalResearch #MedicalAdvancements

"Lp(a) and LDL-C Management: Exploring Divergent Perspectives" is now available on LipidCME with Drs. James Underberg, Christie Ballantyne, Alan Brown MD MHA FACC FAHA FASPC MNLA, and Payal Kohli, MD, FACC.   In this #CME activity, experts will enhance the knowledge, skills, and performance of the healthcare team, emphasizing shared decision-making and interprofessional coordination of patient care. They appraise clinical evidence for both conventional and investigational therapies for Lp(a) management, and consider the safety and efficacy of current and emerging LDL-C reduction therapies in patients with ASCVD   This activity is supported by educational funding provided by Esperon Therapeutics, NewAmsterdam Pharma, and Novartis Pharmaceuticals   To participate, click this link: https://ow.ly/3Ioi50SXXnF

Check out this article from Pharmaceutical Executive. The global radiopharmaceutical market is on track to grow from $9.07 billion in 2023 to an impressive $26.51 billion by 2031, fueled by advancements in diagnostic and therapeutic applications for conditions like cancer and Alzheimer’s disease. Established markets in North America continue to benefit from robust infrastructure and innovation in theranostics and AI-driven personalized medicine. This evolution is a game-changer in healthcare, promising enhanced treatment precision and expanded patient access worldwide. Read the full article: https://bit.ly/3O14fcZ #Radiopharmaceuticals #HealthcareInnovation #Theranostics

What are #Biosimilars? Glad you asked! Biosimilars create a broader range of cost-effective alternatives to reference biologics for healthcare providers. At Teva, we work relentlessly to transform every aspect of biologic drug development to improve speed and efficiency and maximize the value of biologics. This #GlobalBiosimilarsWeek, learn how biosimilars help bring affordable medicines to patients and savings to healthcare systems. Discover more here. #GlobalBiosimilarsWeek #biosimilars #TevaBiosimilarsUnlockingValue #Tevapharm #TeamTeva

🌟 Unlocking Insights into the #PolycythemiaVeraMarket 🌟 According to DelveInsight Business Research LLP, Dive into the evolving landscape of the Polycythemia Vera Market, uncovering insights into current trends, market dynamics, therapeutic advancements, and future opportunities. The leading #PolycythemiaVeraCompanies such as Protagonist Therapeutics, IMAGO BIOSCIENCES LTD, Italfarmaco, Silence Therapeutics plc, Ionis Pharmaceuticals, Inc. and many others. 🔗 Explore the complete report now to stay ahead in this niche market @ https://lnkd.in/dVusRkPB #PolycythemiaVera #MarketInsights #DelveInsight #HealthcareMarketResearch #PharmaMarket #TherapeuticAdvancements

 Neuren Pharmaceuticals Limited (ASX: NEU) is Set to Gain $50M to Boost Drug Development Pipeline 💼 At the time of writing, Neuren Pharmaceuticals Limited (ASX: NEU) has secured a significant financial boost from the recent sale of a Rare Pediatric Disease Priority Review Voucher (PRV), a strategic move by its U.S. partner, Acadia Pharmaceuticals (NASDAQ: ACAD). The voucher, sold for $150 million following FDA approval of DAYBUE (trofinetide) for Rett syndrome, entitles Neuren to roughly $50 million—a powerful endorsement of its neurodevelopmental drug pipeline. This payout is set to fuel further investment in groundbreaking therapies for neurodevelopmental conditions. Currently, Neuren’s shares are trading at $12.98, marking a 5.8% increase. 🌐 https://lnkd.in/gk5iWXG4 hashtag #PharmaNews hashtag #Biotech hashtag #FDAApproval hashtag #NEU hashtag #ASX hashtag #HealthcareInnovation

Thoughts on this? >> Nuvalent's $350M offering; FDA lifts partial hold on Zentalis drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing

Sales at ex-factory prices in the Swiss pharmaceutical market rose by 4.9% According to a recent press release by vips Vereinigung Pharmafirmen in der Schweiz and Interpharma in collaboration with IQVIA, the Swiss pharmaceutical market saw a 4.9% increase in sales in 2023, reaching 7.4 billion Swiss francs despite a curbing effect of 2.7% due to price cuts. Key growth areas included oncology, autoimmune diseases and antivirals, reflecting the sector’s commitment to innovation. Generics and biosimilars also recorded significant growth, underscoring the market’s adaptability. The Swiss pharma market, known for its robust growth, is a hub for innovative drugs and treatment methods, making it a leading center for healthcare advancements. We make it our mission to help biotechnology companies thrive in this market and combine economic success with health improvements. Visit our blog for more insights and graphics on this topic: https://lnkd.in/dAHbrjdG #SwizzardPharma #HealthcareInnovation #MarketGrowth Michael Zürcher, PhD EMBA | Bettina Schelbert | Karin Senn

The Swiss pharmaceutical market’s performance in 2023 reflects a robust industry that is characterized by commitment to innovation and responsiveness to regulatory and economic pressures. For biotech and pharma companies, these trends represent significant opportunities for growth and contribution to global healthcare advancements.

Chronic Plaque Psoriasis Market Size is expected to grow at a CAGR of 2.8% during the forecast period (2024-2034), estimates DelveInsight The leading #ChronicPlaquePsoriasisCompanies such as ALZA Inc, DE, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma S/A Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus BioSciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Corporation Tanabe Pharma, APOPHARMA, Cellceutix Corporation, Kadmon, a Sanofi Company, LLC, Novartis, Coherus BioSciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others. Stay ahead with key market forecasts, ongoing clinical trials, and breakthrough therapies shaping the future of psoriasis management. Click Here for Report @ https://lnkd.in/eun3xUna #ChronicPlaquePsoriasis #PsoriasisMarket #HealthcareInsights #MarketAnalysis #DelveInsight